Figure 1 Characterization of these Cap-3M2e VLPs.

(a) Primary pattern structure of six recombinant Cap-3M2e. (b) M2e sequence of the human, swine and avian IAV which were used in challenging experiment. (c) Schematic illustration of Cap-3M2e VLPs nanovaccine. The VLPs model was derived from the PDB database (3R0R). (d) SDS-PAGE analysis of these purified Cap-3M2e proteins. Lane M: molecular weight markers; lane 1: Cap; lane 2: Cap-hsaM2e; lane 3: Cap-hasM2e; lane 4: Cap-shaM2e; lane 5: Cap-sahM2e; lane 6: Cap-ahsM2e; lane 7: Cap-ashM2e. (e) Transmission electron micrograph (TEM) of Cap-3M2e VLPs. The image is part of the TEM of Cap-ashM2e VLPs. Scale bars = 50 nm. (f) Size distribution of these Cap-3M2e VLPs (n=5). (g) Zeta potential of these Cap-3M2e VLPs (n=5).